Step (or leap) into the future. What is new in 2000 and beyond? An emphasis on endocrine failure

  • A. E. Baue
Conference paper


This paper is my annual oration on prevention of multiple organ dysfunction syndrome (MODS) and multiple organ failure (MOF) at the Organ Failure Academy in Trieste, Italy. All we can do to treat MODS and MOF is organ support. Therefore, prevention is the key — supporting organ and system function before dysfunction or failure occur. There are many ways we can do that in 2002.1 have reviewed them [1,2]. The future was predicted recently by a number of authorities in intensive care medicine and anaesthesiology who were plenary speakers at the recent Society of Critical Care Medicine meeting. Buchman talked about the new junction of genomics and critical care as it exists today and as it is likely to evolve tomorrow, van der Pol reviewed tissue factor and activated protein C, which may also improve other inflammatory pathways. Abraham reviewed genetic analyses and predicted that they may help determine future therapies in critically ill patients. Tracy said that it should be feasible to study both vagus nerve stimulation and anti-HMGB-1 (a latent mediator). Vincent reviewed future therapeutic interventions that will likely involve multiple/combination therapies. Genomics and critical care, tissue factor and activated protein C, genetic analysis, latent mediators, and other problems, and the possibility of multiple or combination therapy are on the horizon. This last recommendation comes because factors to either block or stimulate individual mediators or anti-inflammatory agents have failed. The real question is how quickly these predictions will help our patients. The world of science and molecular biology is exciting but much of it is pure science and is not yet related to improved care in the intensive care unit (ICU) or operating room.


Septic Shock Severe Sepsis Acute Respiratory Distress Syndrome Septic Patient Chronic Granulomatous Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Baue AE (2000) MODS/MOF A complication of progress in organ support. Shock 13:A7Google Scholar
  2. 2.
    Baue AE (2002) Sepsis and organ dysfunction — basics, controversies, rationale. In: Baue AE, Berlot TG, Gullo A, Vincent JL (eds) Springer-Verlag Italia, Milan, pp 19–34Google Scholar
  3. 3.
    Rees J (2002) Complex disease and the new clinical sciences. Science 296:698–672PubMedCrossRefGoogle Scholar
  4. 4.
    Simon H (1991) Models of my life. Basic Books, NYGoogle Scholar
  5. 5.
    Nathan DC (2002) Careers and translational clinical research - historical perspectives, future challenges. JAMA 287:2424–2427PubMedCrossRefGoogle Scholar
  6. 6.
    Brenneman FD, Wright JG, Kennedy ED, et al (1999) Outcomes research in surgery. World J Surg 23:1220–1223PubMedCrossRefGoogle Scholar
  7. 7.
    Sackett DL, Rosenberg WMC (1995) The need for evidence-based medicine. J Roy Soc Med 88:620–624PubMedGoogle Scholar
  8. 8.
    Cohen J (1999) The failure of clinical trials in sepsis. Curr Opm Healthcare X:339–340Google Scholar
  9. 9.
    Marshall JC, Vincent JL, Fink MP, et al Measures, markers and mediators: towards a staging system for clinical sepsis. Crit Care Med (in press)Google Scholar
  10. 10.
    Torpy JM (2002) New threats and old enemies — challenges for critical care medicine. JAMA 287:1513–1515PubMedCrossRefGoogle Scholar
  11. 11.
    Davidson A, Diamond B (2001) Autoimmune diseases. N Engl J Med 345:340–350PubMedCrossRefGoogle Scholar
  12. 12.
    Kamradt T, Mitchison NA (2001) Tolerance and autoimmunity. N Engl J Med 344:655–664PubMedCrossRefGoogle Scholar
  13. 13.
    Kazatchkine MD, Kaveri SV (2001) Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345:747–755PubMedCrossRefGoogle Scholar
  14. 14.
    Choy EHS, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907–916PubMedCrossRefGoogle Scholar
  15. 15.
    Sartor RB (2000) New therapeutic approaches to Crohn’s disease. N Engl J Med 342:1664–1666PubMedCrossRefGoogle Scholar
  16. 16.
    Safar PJ, Kochanek PM (2002) Genes, microbes, and T cells — new therapeutic targets in Crohn’s disease. N Engl J Med 346:614–616CrossRefGoogle Scholar
  17. 17.
    Gallin JI, Malech RS, Weening RS, et al (1991) A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med 324:509–516CrossRefGoogle Scholar
  18. 18.
    Gorman JD, Sack KE, Davis JC (2002) Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 346:1349–1356PubMedCrossRefGoogle Scholar
  19. 19.
    Dayer JM, Krane SM (2002) Anti-TNF-alpha therapy for ankylosing spondylitis — a specific or nonspecific treatment? N Engl J Med 346:1399–1400PubMedCrossRefGoogle Scholar
  20. 20.
    Saenz JJ, Izura JJ, Manrique A, et al (2001) Early prognosis in severe sepsis via analyzing the monocyte immunophenotype. Intensive Care Med 27:970–977PubMedCrossRefGoogle Scholar
  21. 21.
    Haupt W, Beyer A, Schoolmann S, et al (2000) Early depression and late improvement of HLA-DR and LPS-stimulated IL-6/TNfa production in survivors of sepsis. Shock 13:A498Google Scholar
  22. 22.
    Schroeder S, Wichers M, Klingmueller D (2001) The hypothalamic-pimitary adrenal axis of patients with severe sepsis: altered response to corticotropin releasing hormone. Crit Care Med 29:310–316PubMedCrossRefGoogle Scholar
  23. 23.
    Fischer G, Schneider EM, Moldawer LL, et al (2001) CD64 surface expression on neutrophils is transiently upregulated in patients with septic shock. Intensive Care Med 27:1848–1852PubMedCrossRefGoogle Scholar
  24. 24.
    Hirsh M, Mahamid E, Bashenko Y, et al (2001) Overexpression of the high-affinity Fc X receptor (CD64) is associated with leukocyte dysfunction in sepsis. Shock 16:102–108PubMedCrossRefGoogle Scholar
  25. 25.
    Cobb JP, Laramie JM, Qiu Y, et al (2001) Broad-scale splenic gene expression profihng in septic patients with multiple organ dysfunction syndrome (abstract). Soc U Surgeons Program 37Google Scholar
  26. 26.
    Krafte-Jacobs B, Bock GH (2001) Circulating erythropoietin and interleukin-6 concentrations increase in critically ill children with sepsis and septic shock. Crit Care Med 29:S151-S155CrossRefGoogle Scholar
  27. 27.
    Pellegrini J, Puyana JC, Lapchak P, Miller C (2001) A membrane TNEa/TNER ratio correlates to MOD score and mortahty (abstract). Shock 18:20Google Scholar
  28. 28.
    Mitsuoka H, Kistler EB, Schmid-Schonbein GW (2002) Protease inhibition in the intestinal lumen: attenuation of systemic inflammation and early indicators of multiple organ failure in shock. Shock 17:205–209PubMedCrossRefGoogle Scholar
  29. 29.
    Kasai T, Endo S, Yamada Y, et al (1999) Nitrite/nitrate and type II phospholipase A2 increase in patients with multiple organ dysfunction syndrome. Shock [Suppl 12]:A62Google Scholar
  30. 30.
    Weighardt H, Heidecke CD, Westerhold A, et al (2002) Impaired monocyte IL-12 production before surgery as a predictive factor for the lethal outcome of postoperative sepsis. Ann Surg 235:560–565PubMedCrossRefGoogle Scholar
  31. 31.
    Oberholzer A, Steckholzer U, Kurimoto M, et al (2001) Interleukin-18 plasma levels are increased in patients with sepsis compared to severe injured patients. Shock 16:411–414PubMedCrossRefGoogle Scholar
  32. 32.
    Hauser AR, CObb E, Bodi M, et al (2002) Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-assisted pneumonia caused by Pseudomonas aeurginosa. Crit Care Med 30:521–524PubMedCrossRefGoogle Scholar
  33. 33.
    Abraham E (2002) Mechanisms of cytokine activation in septic patients in the medical ICU. SCCM Symposium Highlights, pp 19–22Google Scholar
  34. 34.
    Mavrommatis AC, Theodoridis T, Economou M, et al (2001) Activation of the fibrinolytic system and utilization of the coagulation inhibitors in sepsis: comparison with severe sepsis and septic shock. Intensive Care Med 27:1853–1859PubMedCrossRefGoogle Scholar
  35. 35.
    Barth E, Fischer G, Maier A, et al (2000) Peaks of endogenous G-CSF semm concentrations are followed by an increase in burst activity of neutrophils in most patients with severe sepsis and septic shock. Shock 13:A414Google Scholar
  36. 36.
    Luger A, Graf H, Schwarz HP, et al (1986) Decreased semm interleukin 1 activity and monocyte interleukin 1 production in patients with fatal sepsis. Crit Care Med 14:458–463PubMedCrossRefGoogle Scholar
  37. 37.
    Nijsten MWN, Duis HJT, Zijlstra JG, et al (2000) Blunted rise in platelet count in critically ill patients is associated with worse outcome. Crit Care Med 28:3843–3846PubMedCrossRefGoogle Scholar
  38. 38.
    Papathanassoglou EDE, Moynihan JA, McDermott MP, et al (2001) Expression of Fas (CD95) and Fas ligand on peripheral blood mononuclear cells in critical illness and association with multiorgan dysfunction severity and survival. Crit Care Med 29:709–718PubMedCrossRefGoogle Scholar
  39. 39.
    Bmemmer-Smith S, Stuber F, Schroeder S (2001) Protective functions of intracellular heat-shock protein (HSP) 70-expression in patients with severe sepsis. Intensive Care Med 27:1835–1841CrossRefGoogle Scholar
  40. 40.
    Liacos C, Katsaragakis S, Konstadoulakis MM, et al (2001) Apoptosis in cells of bronchoalveolar lavage: a cellular reaction in patients who die with sepsis and respiratory failure. Crit Care Med 29:2310PubMedCrossRefGoogle Scholar
  41. 41.
    Calvano JE, Agnese DM, Hahm SJ, et al (2001) Human toll-like receptor-4 (hTLR4) mutations are associated with an increased risk of gram-negative infections and increased mortahty. Surg Fomm 52:133–134Google Scholar
  42. 42.
    Bakker J, Gris P, Coffemils M, et al (1996) Serial blood lactate levels can predict the development of multiple organ failure following septic shock. Am J Surg 171:221–226PubMedCrossRefGoogle Scholar
  43. 43.
    Hartemink KJ, Groeneveld J, Groot MCM de, et al (2001) a-Atrial natriuretic peptide, cyclic guanosine monophosphate, and endothelin in plasma as markers of myocardial depression in human septic shock. Crit Care Med 29:80–85Google Scholar
  44. 44.
    Claeys R, Vinken S, Spapen H, et al (2002) Plasma procalcitonin and C-reactive protein in acute septic shock: clinical and biological correlates. Crit Care Med 30:757–762PubMedCrossRefGoogle Scholar
  45. 45.
    Russwurm S, Vickers J, Meier-Hellmann A, et al (2002) Platelet and leukocyte activation correlate with the severity of septic organ dysfunction. Shock 17:263–268PubMedCrossRefGoogle Scholar
  46. 46.
    Tavares-Murta BM, Zaparoh M, Ferreira RB, et al (2002) Failure of neutrophil chemotactic function in septic patients. Crit Care Med 30:1056–1061PubMedCrossRefGoogle Scholar
  47. 47.
    Stephan F, Yang K, Tankovic J, et al (2002) Impairment of polymorphonuclear neutrophil functions precedes nosocomial infections in critically ill patients. Crit Care Med 30:315–322PubMedCrossRefGoogle Scholar
  48. 48.
    Bemard G, Vincent J, Laterre PF, et al (2001) The PROWESS Trial — efficacy and safety of recombinant human-activated protein C for severe sepsis. N Engl J Med 344:699–708CrossRefGoogle Scholar
  49. 49.
    Grinnell BW, Joyce D (2001) Recombinant human activated protein C: a system modulator of vascular function for treatment of severe sepsis. Crit Care Med 29:S53-S61PubMedCrossRefGoogle Scholar
  50. 50.
    Bemard G, Artigas A, Dellinger P, et al (2001) Clinical expert round table discussion (session 3) at the Margaux Conference on Critical Illness: the role of activated protein C in severe sepsis. Crit Care Med 29:S75-S77CrossRefGoogle Scholar
  51. 51.
    Raufhake C, Schleuter B, Driller B, et al (1999) Tumor necrosis factor gene polymorphism in critically ill surgical patients: its influence on susceptibihty to and outcome of sepsis (abstract). Crit Care Med 27:A97CrossRefGoogle Scholar
  52. 52.
    Gibot S, Cariou A, Drouet L, et al (2002) Association between a genomic polymorphism within the CD 14 locus and septic shock susceptibility and mortahty rate. Crit Care Med 30:969–973PubMedCrossRefGoogle Scholar
  53. 53.
    Ma P, Chen D, Pan J, Du B (2002) Genomic polymorphism with interleukin-1 family cytokines influences the outcome of septic patients. Crit Care Med 30:1046–1050PubMedCrossRefGoogle Scholar
  54. 54.
    Kumar A, Kumar A, Parrillo JE (2002) Interleukin-1 gene cluster polymorphisms: all in the family. Crit Care Med 30:1168–1169PubMedCrossRefGoogle Scholar
  55. 55.
    Randolph AG (2002) Mining for the genetic determmants of septic shock: when is it really gold? Crit Care Med 30:1161–1163PubMedCrossRefGoogle Scholar
  56. 56.
    Cariou A, Chiche JD, Charpentier J, et al (2002) The era of genomics: impact on sepsis clinical trial design. Crit Care Med 30:S341-S348PubMedCrossRefGoogle Scholar
  57. 57.
    Willett WC (2002) Balancing life-style and genomics research for disease prevention. Science 296:695–698PubMedCrossRefGoogle Scholar
  58. 58.
    Strohman R (2002) Maneuvering in the complex path from genotype to phenotype. Science 296:701–703PubMedCrossRefGoogle Scholar
  59. 59.
    Roos D, Winterboum CC (2002) Lethal weapons. Science 296:669–670PubMedCrossRefGoogle Scholar
  60. 60.
    Baue AE, Gunther B, Hartl W, et al (1984) Altered hormonal activity in severely ill patients after injury or sepsis. Arch Surg 119:1125–1132PubMedCrossRefGoogle Scholar
  61. 61.
    Sibbald WS, Short A, et al (1977) Variations in adreno-corticol responsiveness during severe bacterial infection: umecognized adreno-corticol insufficiency in severe bacterial infections. Ann Surg 186:29–33PubMedCrossRefGoogle Scholar
  62. 62.
    Leeuwen HJ van, Brüggen T van der, Asbeck BS van, Boereboom FTJ (2001) Effect of corticosteroids on nuclear factor-kB activation and hemodynamics in late septic shock. Crit Care Med 29:1074–1077PubMedCrossRefGoogle Scholar
  63. 63.
    Annane D (2000) Effects of the combination of hydrocortisone (HC) — fludro-cortisone (FC) on mortahty in septic shock. Crit Care Med 28: [Suppl] A63Google Scholar
  64. 64.
    Beishuizen A, Thijs LG, Vermes I (2001) Patterns of corticosteroid-binding globulin and the free Cortisol index during septic shock and multitrauma. Intensive Care Med 27:1584–1591PubMedCrossRefGoogle Scholar
  65. 65.
    Kees H, Polderman JJS, Wester JP (2000) High incidence of adreno-cortical insufficiency in patients with a mutiple organ dysfunction syndrome. Crit Care Med 28:a49CrossRefGoogle Scholar
  66. 66.
    Zaloga GP (2001) Sepsis-induced adrenal deficiency syndrome. Crit Care Med 29:88–89CrossRefGoogle Scholar
  67. 67.
    Namba H, Fujimura N, Imaizumi H, et al (2000) Effect of methylprednisolone on inflammatory response in septic shock patients. Crit Care Med 28: [Suppl] A613/T201Google Scholar
  68. 68.
    Burton TM (2002) Cheap drugs that halt fatal sepsis unused. The Day. New London, Conn., Saturday May 18Google Scholar
  69. 69.
    Ligtenberg JJM, Girbes ARJ, Beentjes JAM, et al (2001) Hormones in the critically ill patient: to intervene or not to intervene? Intensive Care Med 27:1567–1577PubMedCrossRefGoogle Scholar
  70. 70.
    Sharshar T, Calier R, Blanchard A, et al (2002) Depletion of neurohypophyseal content of vasopressin in septic shock. Crit Care Med 30:497–500PubMedCrossRefGoogle Scholar
  71. 71.
    Meduri GU, Cinn AJ, Leeper KV (1994) Corticosteroid rescue treatment of progressive fibro- proliferation in late ARDS. Chest 105:1516–1527PubMedCrossRefGoogle Scholar
  72. 72.
    Nagelschmidt M, Neugebauer E (2000) Improvement of outcome after abdominal surgery by perioperative high dose methylprednisolone. Shock 13:A635Google Scholar
  73. 73.
    Brown CJ, Buie WD (2001) Perioperative stress dose steroids: do they make a difference? J Am Coll Surg 193:678–686PubMedCrossRefGoogle Scholar
  74. 74.
    Koo DJ, Jackman D, Chaudry IH, Wang P (2001) Adrenal insufficiency during the late stage of polymicrobial sepsis. Crit Care Med 29:618–622PubMedCrossRefGoogle Scholar
  75. 75.
    Woolf PD (2001) Adrenal tea leaves: is the adrenal response to sepsis discernible? Crit Care Med 29:450–451PubMedCrossRefGoogle Scholar
  76. 76.
    Matot I, Sprung CL (1998) Corticosteroids in septic shock: resurrection or the last rites? Crit Care Med 26:627–630PubMedCrossRefGoogle Scholar
  77. 77.
    Briegel J (2000) Hydrocortisone and the reduction of vasopressors in septic shock: therapy or only chart cosmetics? Intensive Care Med 26:1723–1726PubMedCrossRefGoogle Scholar
  78. 78.
    Polderman KH, Spijkstra JJ, Wester JP, et al (2000) High incidence of adrenocortical insufficiency in patients with the multiple organ dysfunction syndrome. Crit Care Med 28:A49CrossRefGoogle Scholar
  79. 79.
    Schultz SG (1996) Homeostasis, humpty dumpty and integrative biology news. Physiol Sci 11:238–246Google Scholar
  80. 80.
    Buchman TG (1996) Physiologic stability and physiologic state. J Trauma 41:599–605PubMedCrossRefGoogle Scholar
  81. 81.
    Siegel JH, Farrell EF, Goldwyn RM, Friedman HP (1972) The surgical imphcations of physio logic patterns in myocardial infarction shock. Surgery 72:126–141PubMedGoogle Scholar
  82. 82.
    Chambers NK, Buchman TG (2001) Shock at the millennium H. Cannon WB and Henderson L. Shock 16:278–284PubMedCrossRefGoogle Scholar
  83. 83.
    Goodwin JS (1997) Chaos and the hmits of modem medicine. JAMA 278:1399–1400PubMedCrossRefGoogle Scholar
  84. 84.
    Latour B (1998) From the world of science to the world of research. Science 280:208–209CrossRefGoogle Scholar
  85. 85.
    Goldberger AL, Rigney DR, West BJ (1990) Chaos and fractals in human physiology. Sci Am 262:43–49CrossRefGoogle Scholar
  86. 86.
    Seely AJE, Christou NV (2000) Multiple organ dysfunction syndrome: exploring the paradigm of complex non-linear systems. Crit Care Med 28:2193–2200PubMedCrossRefGoogle Scholar
  87. 87.
    Knox J, Demling R, Wilmore D, et al (1995) Increased survival after major thermal injury: the effect of growth hormone therapy in adults. J Trauma 39:526–530PubMedCrossRefGoogle Scholar
  88. 88.
    Kirton O, Windsor J, Civetta J, et al (1996) Persistent uncorrected intermucosal pH in injured patient: the impact of splechnic and anti-oxidant therapy. Crit Care Med 24:80–82Google Scholar
  89. 89.
    Baue AE (2001) Bad and good news in prevention and management of sepsis and MODS. Minerva Anestesiol 67:773–783PubMedGoogle Scholar
  90. 90.
    Baue AE (2001) Semmelweis Lecture: sepsis research — What did we do wrong? What would Semmelweis do today? Shock 16:1–8PubMedCrossRefGoogle Scholar
  91. 91.
    Candiani NA (2001) Infection surveillance in ICUs. Minerva Anestesiol 67:839–847PubMedGoogle Scholar
  92. 92.
    Barie PS (2001) Infection control is a matter of self control. Surg Infect 2:253–254CrossRefGoogle Scholar
  93. 93.
    Murray JA, Belzberg H, Chen D, et al (1999) Prospective evaluation of early fluconazole use in the surgical ICU. Shock 18:35–40Google Scholar
  94. 94.
    Zandstra DF, Saene HKF van (2001) Selective decontamination of the digestive system as infection prevention in the critically ill. Does it lead to resistance? Minerva Anestesiol 67 292–297PubMedGoogle Scholar
  95. 95.
    Mannning A (2002) Staph vaccine reduces infection risk from hospitals. USA TODAY Tuesday April 25Google Scholar
  96. 96.
    Geerts L, Jorens PG, Willems J, et al (2001) Natural inhibitors of neutrophil function in acute respiratory distress syndrome. Crit Care Med 29:1920–1924PubMedCrossRefGoogle Scholar
  97. 97.
    Zeiher BG, Matsuoka S, Kawabata K, Repine JE (2002) Neutrophil elastase and acute lung injury: prospects for sivelestat and other neutrophil elastase inhibitors as therapeutics. Crit Care Med 30:S281-S286PubMedCrossRefGoogle Scholar
  98. 98.
    Tanowitz HB, Weiss LM, Chan J (2002) Neutrophil migration and sepsis. Crit Care Med 30:1169–1170PubMedCrossRefGoogle Scholar
  99. 99.
    Grafhorst JP van, Foudraine NA, Nooteboom F, et al (2002) Unexpected high risk of contamination with staphylococci species attributable to standard preparation of syringes for continuous intravenous dmg administration in a simulation model in intensive care units. Crit Care Med 30:833–836PubMedCrossRefGoogle Scholar
  100. 100.
    Koss WG, Khalili TM, Lemus JF (2002) Nosocomial pneumonia is not prevented by protective contact isolation in the surgical intensive care unit. J Am Coll Surg 297:1140–1148Google Scholar
  101. 101.
    Wang P, Zheng FB, Zhou M, et al (1993) Pentoxifylline restores cardiac output and tissue perfusion after trauma-hemorrhage and decreases susceptibility to sepsis. Surgery 114:352–359PubMedGoogle Scholar
  102. 102.
    Bacher A, Mayer N, Klimscha W, et al (1997) Effects of pentoxifylline on hemodynamics and oxygenation in septic and nonseptic patients. Crit Care Med 25:795–800PubMedCrossRefGoogle Scholar
  103. 103.
    Fourrier F, Chopin C, Huart JJ, et al (1993) Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 104:882–888PubMedCrossRefGoogle Scholar
  104. 104.
    Inthom D, Hoffmann JN, Hartl WH, et al (1997) Antithrombin III supplementation in severe sepsis: Beneficial effects on organ dysfunction. Shock 8:328–334CrossRefGoogle Scholar
  105. 105.
    Bryg DJ, Beale RJ (1998) Clinical effects of enteral immunonutrition on intensive care patients: a meta-analysis. Crit Care Med 26:A91CrossRefGoogle Scholar
  106. 106.
    Durham RM, Neunaber K, Mazuski JE, et al (1996) The use of oxygen consumption and delivery as endpoints for resuscitation in criticaUy ill patients. J Trauma 41:32–40PubMedCrossRefGoogle Scholar
  107. 107.
    Avontour JA, Tutein Nolthenius RP, Bodegom JW van, Bmining HA (1998) Prolonged inhibition of nitric oxide synthesis in severe septic shock. Crit Care Med 26:660–667CrossRefGoogle Scholar
  108. 108.
    Ishikawa K, Tanaka H, Nakamori Y, et al (2000) Difference in the responses followmg granulocyte colony-stimulating factor (G-CSF) administration to septic patients with relative neutropenia. J Trauma Injury Infect Crit Care 48:814–825CrossRefGoogle Scholar
  109. 109.
    Philhps JO, Metzler MH, Palmieri MTL, et al (1996) A prospective smdy of simphfied omeprazole suspension for the prophylaxis of stress-related mucosal damage. Crit Care Med 24:1793–1800CrossRefGoogle Scholar
  110. 110.
    O’Keefe GE, Gentilello LM, Maier RV (1998) Incidence of infectious complications associated with the use of histamine2-receptor antagonists in critically ill trauma patients. Ann Surg 227:120–125PubMedCrossRefGoogle Scholar
  111. 111.
    Sun X, Wagner DP, Knaus WA (1996) Does selective decontamination of the digestive tract reduce mortahty for severely ill patients? Crit Care Med 24:753–755PubMedCrossRefGoogle Scholar
  112. 112.
    Luiten EJ, Hop WCJ, Lange JF, Bruining HA (1995) Controlled clmical trial of selective decontamination for the treatment of severe acute pancreatitis. Ann Surg 222:57–65PubMedCrossRefGoogle Scholar
  113. 113.
    Dellinger RP, Zinmierman JL, Taylor RW, et al (1998) Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Crit Care Med 26:15–23PubMedCrossRefGoogle Scholar
  114. 114.
    Zapol WM (1998) Nitric oxide inhalation in acute respiratory distress syndrome: it works, but can we prove it? Crit Care Med 26:2–3PubMedCrossRefGoogle Scholar
  115. 115.
    Mathisen DJ, Kuo EY, Hahn C, et al (1998) Inhaled nitric oxide for adult respiratory distress syndrome after pulmonary resection. Ann Thorac Surg 65:1894–1902CrossRefGoogle Scholar
  116. 116.
    Shoemaker WC, Appel PL, Kram HB, et al (1988) Prospective trial of supranormal values of survivors as therapeutic goals in high-risk surgical patients. Chest 94:1176–1188PubMedCrossRefGoogle Scholar
  117. 117.
    Thangathurai D, Charbonnet C, Wo CCJ, et al (1996) Intraoperative maintenance of tissue perfusion prevents ARDS. New Horiz 4:466–474PubMedGoogle Scholar
  118. 118.
    Kingsnorth AN, Galloway SW, Formela LJ (1995) Randomized, double-blind phase II trial of lexipafant, a platelet-activating factor receptor antagonist in human acute pancreatitis. Br J Surg 82:1414–1420PubMedCrossRefGoogle Scholar
  119. 119.
    Hirasawa H, Sugai T, Oda S, et al (1998) Continuous hemodiafiltration (Chdf) removes cytokine and improves respiratory index (Ri) and oxygen metabohsm in patients with acute respiratory distress syndrome (Ards). Crit Care Med 26:A120CrossRefGoogle Scholar
  120. 120.
    Honore PM, James J, Wauthier M, et al (1998) Reversal of intractable circulatory failure complicating septic shock with short time high volume haemofiltration (ST-HV-CWH) after failure of conventional therapy: a prospective evaluation. Crit Care Med 2:62CrossRefGoogle Scholar
  121. 121.
    Kolla S, Awad SS, Rich PB, et al (1997) Extracorporeal life support for 100 aduh patients with severe respiratory failure. Ann Surg 226:544–566PubMedCrossRefGoogle Scholar
  122. 122.
    Gentielello LM, Jurkovich GJ, Stark MS, et al (1997) Is hypothermia in the victim of major trauma protective or harmful? Ann Surg 226:439–449CrossRefGoogle Scholar
  123. 123.
    Meijer C, Wiezer MJ, Hack CE, et al (2001) Coagulopathy following major liver resection: the effect of rBPI21 and the role of decreased synthesis of regulating proteins by the liver. Shock 15:261–271PubMedCrossRefGoogle Scholar
  124. 124.
    Wall P, Foley M, Raymond F, et al Enalaprilat during resuscitation increases temperamre and improves survival. Shock [Suppl 11] 99:A77Google Scholar
  125. 125.
    Forceville X, Vitoux D, Gauzit R, et al (1998) Selenium systemic immune response syndrome, sepsis and outcome in cktically ill patients. Crit Care Med 26:1536–1544PubMedCrossRefGoogle Scholar
  126. 126.
    Vincent JL, Brasse R, Santman F, et al (2001) A multi-centre, double-blind, placebo-controlled study of liposomal prostaglandin El (TLC C-53) in patients with acute respiratory distress syndrome. Intensive Care Med 27:1578–1583PubMedCrossRefGoogle Scholar
  127. 127.
    Fronhoffs S, Luyken J, Steuer K, et al (2000) The effect of CI-esterase inhibitor in definite and suspected streptococcal toxic shock syndrome. Intensive Care Med 26:1566–1570PubMedCrossRefGoogle Scholar
  128. 128.
    Staudinger T, Kofler J, Mullner M, et al (2001) Comparison of prone positioning and continuous rotation of patients with adult respiratory distress syndrome: results of a pilot study. Crit Care Med; 29:51–56PubMedCrossRefGoogle Scholar
  129. 129.
    Lynch RE (2002) Lisofylhne: anti-acute respiratory distress syndrome or just anti-inflammatory? Crit Care Med 30:246–247CrossRefGoogle Scholar
  130. 130.
    Moore EE (1991) Hypertonie sahne dextran for post-injury resuscitation: experimental background and clinical experience. Aust N Z J Surg 61:732–736PubMedGoogle Scholar
  131. 131.
    Shackford SR, Bourguignon PR, Wald SL, et al (1998) Hypertonic sahne resuscitation of patients with head injury: a prospective, randomized clinical trial. J Trauma 44:50–58PubMedCrossRefGoogle Scholar
  132. 132.
    Levine EA, Rosen AL, Sehgal LR, et al (1989) Treatment of acute postoperative anemia with recombinant human erythropoietin. J Trauma 29:1134–1138PubMedCrossRefGoogle Scholar
  133. 133.
    Schinkel C, Licht K, Zedier S, et al (2001) Perioperative treatment with human recombinant interferon-gamma: a randomized double-blind chnical trial. Shock 16:329–333PubMedCrossRefGoogle Scholar
  134. 134.
    Nathens AB, Neff M, Jurkovich GH, et al (2001) Antioxidant supplementation in the critically ill surgical patients. Program of SIS 34:A12Google Scholar
  135. 135.
    Ferrando AA, Sheffield-Moore M, Wolf SE, et al (2001) Testosterone administration in severe bums ameliorates muscle catabolism. Crit Care Med 29:1936–1942PubMedCrossRefGoogle Scholar
  136. 136.
    Napohtano LM (2001) Testosterone administration in male bum patients: the good, the bad, and the ugly. Crit Care Med 29:2032–2033CrossRefGoogle Scholar
  137. 137.
    Choudray-Lucas C, LeBever H, Cynobar L, et al (2000) Omithine a-ketoglutarate improves wound healing in severe bum patients: a prospective randomized double-blind trial versus isonitrogenous controls. Crit Care Med 28:1772–1776CrossRefGoogle Scholar
  138. 138.
    Kirov MY, Evgenov OV, Evgenov NV, et al (2001) Infusion of methylene blue in human septic shock: A pilot, randomized, controlled study. Crit Care Med 29:1860–1867PubMedCrossRefGoogle Scholar
  139. 139.
    Kotani N, Hashimoto H, Kushikata T, et al (2001) Intraoperative prostaglandin El improves antimicrobial and inflammatory responses in alveolar immune cells. Crit Care Med 29:1943–1949PubMedCrossRefGoogle Scholar
  140. 140.
    Byme TA, Persinger RI, Young LS, et al (1999) A new treatment for patients with short bowel syndrome syndrome: growth hormone, glutamine and a modified diet. Ann Surg 222:243–255Google Scholar
  141. 141.
    Takala J, Ruokonen E, Webster NR, et al (1999) Increased mortahty associated with growth hormone treatment in critically ill adults. N Engl J Med 341:785–792PubMedCrossRefGoogle Scholar
  142. 142.
    LuiGen W, Wim LT, Lange JF, Bmining HA (1995) Controlled clinical trial of selective decontamination for the treatment of severe active pancreatitis. Ann Surg 222:57–65CrossRefGoogle Scholar
  143. 143.
    Lingnau W, Berger J, Javorsky F, Benzer HY (1997) Selective gut decontamination in multiple trauma patients. A prospective randomized trial. J Trauma 42:687–694PubMedCrossRefGoogle Scholar
  144. 144.
    Suter PM, Domenighetti G, Schaller M-D, et al (1994) iV-Acetylcysteine enhances recovery from acute lung injury in man: a randomized, double-blind, placebo-controlled clinical study. Chest 105:190–194PubMedCrossRefGoogle Scholar
  145. 145.
    Opal SM, Kessler CM, Roemisch J, Knaub S (2002) Antithrombin, heparin, and heparan sulfate. Crit Care Med 30:S325-S330PubMedCrossRefGoogle Scholar
  146. 146.
    Ledere JR (2002) Platelet glycoprotein Ilb/IIIa antagonists: lessons leamed from clinical trials and future directions. Crit Care Med 30:S332-S340CrossRefGoogle Scholar
  147. 147.
    Douzinas EE, Pitaridis MT, Louris G, et al (2000) Prevention of infection in multiple trauma patients by high-dose intravenous immunoglobulins. Crit Care Med 28:8–15PubMedCrossRefGoogle Scholar
  148. 148.
    Kress HG, Scheideweig C, Schmidt H, Silber R (1999) Reduced incidence of postoperative infection after intravenous administration of an immunoglobulin A-and immunoglobulin M-enriched preparation in anergic patients undergoing cardiac surgery. Crit Care Med 27:1281–1287PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2003

Authors and Affiliations

  • A. E. Baue

There are no affiliations available

Personalised recommendations